Biosignatures was established in 2007 to address a global need for non-invasive, patient friendly and accurate disease diagnosis.
Biosignatures Limited has developed a ‘new test’ which identifies patterns in protein markers from a simple blood sample, which may allow for the earlier diagnosis of diseases, such as cancer.
The assessment of protein markers in a patient’s blood sample will provide clinicians with detailed information about the patient’s disease status.
Blood serum is a complex matrix and contains more than 20,000 proteins some of which are utilised as biomarkers for diagnostic tests in specific disease states e.g. prostate specific antigen (PSA) for the detection of prostate cancer in males. However, the identification of a single biomarker is sometimes inaccurate depending on the specific diagnostic test.
The ‘new test’ developed by Biosignatures will detect changes to numerous proteins that are associated with a particular disease. It is anticipated that this will lead to the identification of specific protein signatures that can be associated with different diseases. These protein signatures will assist clinicians with the early diagnosis of certain diseases.
The Biosignatures test may dramatically improve diagnosis and care pathways for the treatment of patients. The information can be used to assist the clinician to personalise treatment for the individual patient. It would give clinicians more options in monitoring and managing disease states, which could have a major impact on patients’ quality of life
RTC North provided support to Biosignatures Limited by identifying potential collaborators within the NHS in the North East region and facilitating introductory meetings with these groups.
As a result of this support, Biosignatures Limited has formed a collaborative research group with the Department of Endocrinology at Newcastle upon Tyne Hospitals NHS Foundation Trust, to utilise their technology to provide an early diagnostic test for thyroid cancer. The collaborative research group has submitted applications to the i4i programme and to the regional innovation fund managed by the North East Strategic Health Authority.
Biosignatures Limited has also entered into a collaborative study with the Department of Urology at Newcastle upon Tyne Hospitals NHS Foundation Trust. This study will focus on protein signatures associated with diseases relating to the kidney, bladder, and prostate.